scholarly journals Evaluation of the Variability of the ORF34, ORF68, and MLST Genes in EHV-1 from South Korea

Pathogens ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 425
Author(s):  
Hyung-Woo Kang ◽  
Eun-Yong Lee ◽  
Kyoung-Ki Lee ◽  
Mi-Kyeong Ko ◽  
Ji-Young Park ◽  
...  
Keyword(s):  
Nucleotide Sequence ◽  
South Korea ◽  
Molecular Level ◽  
Economic Losses ◽  
Equine Herpesvirus ◽  
Equine Herpesvirus 1 ◽  
Mlst Analysis ◽  
Herpesvirus 1 ◽  
First Time ◽  
Group 1

Equine herpesvirus-1 (EHV-1) is an important pathogen in horses. It affects horses worldwide and causes substantial economic losses. In this study, for the first time, we characterized EHV-1 isolates from South Korea at the molecular level. We then aimed to determine the genetic divergences of these isolates by comparing them to sequences in databases. In total, 338 horse samples were collected, and 12 EHV-1 were isolated. We performed ORF30, ORF33, ORF68, and ORF34 genetic analysis and carried out multi-locus sequence typing (MLST) of 12 isolated EHV-1. All isolated viruses were confirmed as non-neuropathogenic type, showing N752 of ORF30 and highly conserved ORF33 (99.7–100%). Isolates were unclassified using ORF68 analysis because of a 118 bp deletion in nucleotide sequence 701–818. Seven EHV-1 isolates (16Q4, 19R166-1, 19R166-6, 19/10/15-2, 19/10/15-4, 19/10/18-2, 19/10/22-1) belonged to group 1, clade 10, based on ORF34 and MLST analysis. The remaining 5 EHV-1 isolates (15Q25-1, 15D59, 16Q5, 16Q40, 18D99) belonged to group 7, clade 6, based on ORF34 and MLST analysis.

scholarly journals Application of equine herpesvirus-1 vaccine inactivated by both formaldehyde and binary ethylenimine in equine

2021 ◽  
pp. 1815-1821
Author(s):  
Fatma F. Warda ◽  
Hala El Sawy Ahmed ◽  
Nermeen G. Shafik ◽  
Christine A. Mikhael ◽  
Heba M. G. Abd-ElAziz ◽  
...  
Keyword(s):  
Antibody Titer ◽  
Booster Dose ◽  
Economic Losses ◽  
Enzyme Linked Immunosorbent Assay ◽  
Equine Herpesvirus ◽  
Equine Herpesvirus 1 ◽  
Wide Range ◽  
Group A ◽  
Herpesvirus 1 ◽  
Group B

Background and Aim: Equine herpesvirus-1 infection in horses causes a wide range of manifestations affecting the respiratory tract. The virus can cause serious economic losses through sporadic abortion in pregnant mares, perinatal death, respiratory disease in young foals. This study was designed to prepare inactivated equine herpesvirus-1 (EHV-1) vaccine using both 0.005 M binary ethylenimine (BEI) and 0.0006% formaldehyde (FA) to decrease the use of BEI and provide a good immunological response. The efficacy, safety, and duration of immunity of the prepared inactivated EHV-1 vaccine were evaluated. Materials and Methods: The prepared FA/BEI-inactivated EHV-1 vaccine was adjuvanted with Alhydrogel and then evaluated by inoculation into guinea pigs, followed by comparison with the commercial inactivated EHV-1 vaccine. These two vaccines were evaluated by testing the safety and immunogenicity in horses classified into two groups. Group A was vaccinated with two doses of the prepared vaccine at a 4-week interval, while Group B was vaccinated with two doses of the commercial vaccine only. Anti-EHV-1 antibodies were detected in horse serum using enzyme-linked immunosorbent assay (ELISA) and virus neutralizing test (VNT). Results: Regarding the time required to inactivate EHV-1 vaccine, this was decreased using 0.005 M BEI and 0.0006% FA from 24 to 8 h. ELISA in Group A horses demonstrated a significant increase in EHV-1 antibody titer at 2 weeks after the booster dose compared with that for the pre-booster one, from 485 to 855 antibody titer, which then peaked at 1240 in the 3rd month post-vaccination; after that, it began to decline gradually until the 6th month. Meanwhile, in Group B, the ELISA reading increased from 420 to 790 and then peaked at 1215. The VNT mean in Group A increased from 1.1 to 2.5 within 2 weeks after administration of the booster dose, while in Group B it increased from 0.8 to 2.1. Moreover, ELISA in Group A pigs indicated mean antibody titers at the 3rd week post-inoculation of 576 for Group A and 554 for Group B. Conclusion: The inactivated EHV-1 vaccine, with fewer chemicals, was prepared in a shorter time. It is safe and also more potent to protect horses for up to 6 months against EHV-1 infection than the commercially produced vaccine.

The highly O-glycosylated glycoprotein gp2 of equine herpesvirus 1 is encoded by gene 71.

1996 ◽  
Vol 70 (11) ◽  
pp. 8195-8198 ◽  
Author(s):  
J E Wellington ◽  
G P Allen ◽  
A A Gooley ◽  
D N Love ◽  
N H Packer ◽  
...  
Keyword(s):  
Equine Herpesvirus ◽  
Equine Herpesvirus 1 ◽  
Herpesvirus 1

New real-time PCR assay using allelic discrimination for detection and differentiation of equine herpesvirus-1 strains with A2254 and G2254 polymorphisms

2012 ◽  
Vol 32 (10) ◽  
pp. S55-S56
Author(s):  
Kathryn L. Smith ◽  
Yanqiu Li ◽  
Patrick Breheny ◽  
R. Frank Cook ◽  
Pamela J. Henney ◽  
...  
Keyword(s):  
Real Time ◽  
Real Time Pcr ◽  
Equine Herpesvirus ◽  
Pcr Assay ◽  
Allelic Discrimination ◽  
Equine Herpesvirus 1 ◽  
Herpesvirus 1

Infection with Equine Herpesvirus 1 (EHV-1) Strain HVS25A in Pregnant Mice

1999 ◽  
Vol 120 (1) ◽  
pp. 15-27 ◽  
Author(s):  
C. Walker ◽  
V.M. Perotti ◽  
D.N. Love ◽  
J.M. Whalley
Keyword(s):  
Equine Herpesvirus ◽  
Equine Herpesvirus 1 ◽  
Pregnant Mice ◽  
Herpesvirus 1

Argentine strain of equine herpesvirus 1 isolated from an aborted foetus shows low virulence in mouse respiratory and abortion models

2004 ◽  
Vol 103 (1-2) ◽  
pp. 1-12 ◽  
Author(s):  
C.M. Galosi ◽  
C.G. Barbeito ◽  
M.V. Vila Roza ◽  
V. Cid de la Paz ◽  
M.A. Ayala ◽  
...  
Keyword(s):  
Equine Herpesvirus ◽  
Equine Herpesvirus 1 ◽  
Herpesvirus 1
Sign in / Sign up

Export Citation Format

Share Document